Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter earnings call. The company reported solid fourth-quarter results, ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Exane BNP Paribas initiated coverage of Viking Holdings (VIK) with an Outperform rating and $47 price target Light Up your Portfolio with ...

Viking’s stock fell 12.6% to a low of $24.4 following the announcement, due to some investor chatter indicating that the latest news has made the company a potential acquisition target. “It is very ...

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.

Viking Holdings told investors Tuesday during its Q4 earnings call that the company has sold 88% of 2025 inventory, with Viking setting a record for monthly revenue in January and daily revenue on Jan ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral and ...

Both Viking and Roche are attempting to horn in on this market ... The companies plan to sell it both separately and in combination with Roche's CT-388 incretin drug. Image source: Getty Images. Both ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I remain bullish on VKTX stock.

Gerard Bottino / SOPA Images / LightRocket via Getty Images Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter ...

Viking stock soared a year ago on positive clinical trial data from its weight loss drug candidate. That candidate continues to progress, but Viking’s stock has tumbled from its peak.